Market Cap 42.14M
Revenue (ttm) 40,000.00
Net Income (ttm) -8.81M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -22,025.00%
Debt to Equity Ratio 0.00
Volume 155,200
Avg Vol 632,704
Day's Range N/A - N/A
Shares Out 36.65M
Stochastic %K 50%
Beta 1.30
Analysts Strong Sell
Price Target $5.62

Company Profile

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.

Industry: Biotechnology
Sector: Healthcare
Phone: 650 284 4433
Fax: 650 397 4433
Address:
2570 West El Camino Real, Suite 320, Mountain View, United States
JackAnalyst
JackAnalyst Oct. 24 at 2:42 PM
Friday check , $RNXT holding $1.17, green week so far. That $1.15 base holding strong. Waiting on the next catalyst.
0 · Reply
Northern_Lightz
Northern_Lightz Oct. 23 at 7:05 PM
$RNXT reached an important line first patient treated with its patented, FDA-cleared RenovoCath®️. bigger updates likely next.. any thoughts?
0 · Reply
Rnxtsavior
Rnxtsavior Oct. 22 at 9:27 PM
$RNXT Only big news coming here is a Sheeny man reverse split.
0 · Reply
JackAnalyst
JackAnalyst Oct. 22 at 8:35 PM
NK cell therapies are changing the game $254B market ahead. $RNXT’s precision delivery fits right into that future. Could 2026 be the year this story starts to move?
1 · Reply
NAKAttac
NAKAttac Oct. 22 at 5:47 PM
$RNXT Some big news coming at this end of the week!
1 · Reply
Wolfietrader
Wolfietrader Oct. 21 at 4:48 PM
$RNXT this stock cannot figure what to do.
0 · Reply
JackAnalyst
JackAnalyst Oct. 20 at 6:23 PM
Strong Monday open for $RNXT Sitting around $1.17 (+4.5%) by mid-day with steady volume.Feels like buyers are creeping back in after last week’s lull. Watching to see if it can build above $1.20 this week
0 · Reply
Babyhuey
Babyhuey Oct. 20 at 5:51 PM
$RNXT has FDA cleared RenovoCath already generating revenue, TAMP technology used in solid tumors targets medicine where it needs to be instead of systemic poisoning with ugly side effects. TigerPac pancreatic in phase III, 2 interim look showed a 6 month survival advance, DSMB recommended trial to continue. 65% reduction in Adverse events compared to standard of care.
0 · Reply
Babyhuey
Babyhuey Oct. 20 at 5:43 PM
$RNXT the sleeping giant.
0 · Reply
TimmyTheSleuth
TimmyTheSleuth Oct. 20 at 3:12 PM
$RNXT let’s break out of this channel
0 · Reply
Latest News on RNXT
RenovoRx Announces Proposed Public Offering

Feb 6, 2025, 4:05 PM EST - 9 months ago

RenovoRx Announces Proposed Public Offering


RenovoRx CEO Issues Update Letter to Shareholders

May 30, 2024, 8:30 AM EDT - 1 year ago

RenovoRx CEO Issues Update Letter to Shareholders


RenovoRx Announces $11.1 Million at Market Private Placement

Apr 8, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Announces $11.1 Million at Market Private Placement


RenovoRx Highlights Key Leadership Promotions

Mar 8, 2024, 4:05 PM EST - 1 year ago

RenovoRx Highlights Key Leadership Promotions


JackAnalyst
JackAnalyst Oct. 24 at 2:42 PM
Friday check , $RNXT holding $1.17, green week so far. That $1.15 base holding strong. Waiting on the next catalyst.
0 · Reply
Northern_Lightz
Northern_Lightz Oct. 23 at 7:05 PM
$RNXT reached an important line first patient treated with its patented, FDA-cleared RenovoCath®️. bigger updates likely next.. any thoughts?
0 · Reply
Rnxtsavior
Rnxtsavior Oct. 22 at 9:27 PM
$RNXT Only big news coming here is a Sheeny man reverse split.
0 · Reply
JackAnalyst
JackAnalyst Oct. 22 at 8:35 PM
NK cell therapies are changing the game $254B market ahead. $RNXT’s precision delivery fits right into that future. Could 2026 be the year this story starts to move?
1 · Reply
NAKAttac
NAKAttac Oct. 22 at 5:47 PM
$RNXT Some big news coming at this end of the week!
1 · Reply
Wolfietrader
Wolfietrader Oct. 21 at 4:48 PM
$RNXT this stock cannot figure what to do.
0 · Reply
JackAnalyst
JackAnalyst Oct. 20 at 6:23 PM
Strong Monday open for $RNXT Sitting around $1.17 (+4.5%) by mid-day with steady volume.Feels like buyers are creeping back in after last week’s lull. Watching to see if it can build above $1.20 this week
0 · Reply
Babyhuey
Babyhuey Oct. 20 at 5:51 PM
$RNXT has FDA cleared RenovoCath already generating revenue, TAMP technology used in solid tumors targets medicine where it needs to be instead of systemic poisoning with ugly side effects. TigerPac pancreatic in phase III, 2 interim look showed a 6 month survival advance, DSMB recommended trial to continue. 65% reduction in Adverse events compared to standard of care.
0 · Reply
Babyhuey
Babyhuey Oct. 20 at 5:43 PM
$RNXT the sleeping giant.
0 · Reply
TimmyTheSleuth
TimmyTheSleuth Oct. 20 at 3:12 PM
$RNXT let’s break out of this channel
0 · Reply
Luckyluck39
Luckyluck39 Oct. 17 at 1:46 PM
$RNXT waiting for 0.90
0 · Reply
PLX_BULLS
PLX_BULLS Oct. 17 at 3:32 AM
$RNXT When’s the next catalyst?
2 · Reply
Northern_Lightz
Northern_Lightz Oct. 16 at 7:55 PM
What if the next update from $RNXT connects all these dots; platform, advisors, and real data? It would totally change how people view this stock.
0 · Reply
Rnxtsavior
Rnxtsavior Oct. 16 at 2:55 PM
$RNXT Every time they find a new sucker to buy in... Sheeny man sucks it down. So obvious so funny.
1 · Reply
Benjamin47
Benjamin47 Oct. 16 at 9:15 AM
$RNXT Earnings will be out November 13th. >1M revenue is my prediction 🚀
1 · Reply
SocioCobb
SocioCobb Oct. 15 at 11:17 PM
$RNXT 45% return, 3 weeks. God bless the free market!
0 · Reply
Babyhuey
Babyhuey Oct. 15 at 8:40 PM
0 · Reply
NoWeAreNotOkay
NoWeAreNotOkay Oct. 15 at 8:09 PM
$RNXT Great day at RNXT
0 · Reply
Northern_Lightz
Northern_Lightz Oct. 15 at 2:03 PM
Meanwhile $RNXT quietly building its dream team
0 · Reply
CunningStunt69
CunningStunt69 Oct. 14 at 6:58 PM
$RNXT needs about $5 mil a quarter in sales to break even. I do hope they can get there quickly. In the long run if they really can get $400 mil a year in sales they’ll be printing cash.
1 · Reply
Northern_Lightz
Northern_Lightz Oct. 14 at 6:47 PM
$RNXT up again this week. Combine that with two new oncology heavyweights… timing looks interesting.
0 · Reply
Sahil1991
Sahil1991 Oct. 13 at 10:13 PM
$DCTH How does $RNXT compare this story? I looked at $RNXT And liked what I saw, and they seem to be in similar stage (early commercialisation with R&D to broaden indications), sector (oncology), and product (delivery device). They aren’t competing with $DCTH . I invested today…
1 · Reply